Opaleye Management Inc. - Net Worth and Insider Trading
Opaleye Management Inc. Net Worth
The estimated net worth of Opaleye Management Inc. is at least $318 Million dollars as of 2024-12-01. Opaleye Management Inc. is the 10% Owner of Harrow Inc and owns about 3,815,000 shares of Harrow Inc (HROW) stock worth over $160 Million. Opaleye Management Inc. is the 10% Owner of Ocular Therapeutix Inc and owns about 4,918,500 shares of Ocular Therapeutix Inc (OCUL) stock worth over $49 Million. Opaleye Management Inc. is also the 10% Owner of Codexis Inc and owns about 8,545,000 shares of Codexis Inc (CDXS) stock worth over $39 Million. Besides these, Opaleye Management Inc. also holds Eton Pharmaceuticals Inc (ETON) , SANUWAVE Health Inc (SNWV) , TELA Bio Inc (TELA) , Protara Therapeutics Inc (TARA) , TRACON Pharmaceuticals Inc (TCON) . Details can be seen in Opaleye Management Inc.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Opaleye Management Inc. has not made any transactions after 2024-11-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Opaleye Management Inc.
Opaleye Management Inc. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Opaleye Management Inc. owns 6 companies in total, including Eton Pharmaceuticals Inc (ETON) , Protara Therapeutics Inc (TARA) , and TRACON Pharmaceuticals Inc (TCON) among others .
Click here to see the complete history of Opaleye Management Inc.’s form 4 insider trades.
Insider Ownership Summary of Opaleye Management Inc.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ETON | Eton Pharmaceuticals Inc | 2024-10-23 | 10 percent owner |
| TARA | Protara Therapeutics Inc | 2024-09-12 | 10 percent owner |
| TCON | TRACON Pharmaceuticals Inc | 2023-11-10 | 10 percent owner |
 | | 2024-04-25 | 10 percent owner |
| | 2020-01-02 | 10 percent owner |
| | 2022-11-03 | 10 percent owner |
Opaleye Management Inc. Latest Holdings Summary
Opaleye Management Inc. currently owns a total of 8 stocks. Among these stocks, Opaleye Management Inc. owns 3,815,000 shares of Harrow Inc (HROW) as of April 25, 2024, with a value of $160 Million and a weighting of 50.27%. Opaleye Management Inc. owns 4,918,500 shares of Ocular Therapeutix Inc (OCUL) as of January 2, 2020, with a value of $49 Million and a weighting of 15.29%. Opaleye Management Inc. also owns 8,545,000 shares of Codexis Inc (CDXS) as of October 25, 2024, with a value of $39 Million and a weighting of 12.3%. The other 5 stocks Eton Pharmaceuticals Inc (ETON) , SANUWAVE Health Inc (SNWV) , TELA Bio Inc (TELA) , Protara Therapeutics Inc (TARA) , TRACON Pharmaceuticals Inc (TCON) have a combined weighting of 22.13% among all his current holdings.
Latest Holdings of Opaleye Management Inc.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| HROW | Harrow Inc | 2024-04-25 | 3,815,000 | 41.91 | 159,886,650 |
| OCUL | Ocular Therapeutix Inc | 2020-01-02 | 4,918,500 | 9.89 | 48,643,965 |
| CDXS | Codexis Inc | 2024-10-25 | 8,545,000 | 4.58 | 39,136,100 |
| ETON | Eton Pharmaceuticals Inc | 2024-10-23 | 2,770,000 | 13.53 | 37,478,100 |
| SNWV | SANUWAVE Health Inc | 2024-11-01 | 972,002 | 21.00 | 20,412,042 |
| TELA | TELA Bio Inc | 2022-11-03 | 2,072,813 | 3.14 | 6,508,633 |
| TARA | Protara Therapeutics Inc | 2024-09-12 | 1,989,134 | 3.01 | 5,987,293 |
| TCON | TRACON Pharmaceuticals Inc | 2023-11-10 | 0 | 0.04 | 0 |
Holding Weightings of Opaleye Management Inc.
Opaleye Management Inc. Form 4 Trading Tracker
According to the SEC Form 4 filings, Opaleye Management Inc. has made a total of 21 transactions in Harrow Inc (HROW) over the past 5 years, including 21 buys and 0 sells. The most-recent trade in Harrow Inc is the acquisition of 20,000 shares on April 25, 2024, which cost Opaleye Management Inc. around $199,400.
According to the SEC Form 4 filings, Opaleye Management Inc. has made a total of 2 transactions in Ocular Therapeutix Inc (OCUL) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Ocular Therapeutix Inc is the acquisition of 15,000 shares on January 2, 2020, which cost Opaleye Management Inc. around $58,500.
According to the SEC Form 4 filings, Opaleye Management Inc. has made a total of 4 transactions in Codexis Inc (CDXS) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Codexis Inc is the acquisition of 25,000 shares on October 25, 2024, which cost Opaleye Management Inc. around $72,750.
More details on Opaleye Management Inc.'s insider transactions can be found in the Insider Trading History of Opaleye Management Inc. table.Insider Trading History of Opaleye Management Inc.
- 1
Opaleye Management Inc. Trading Performance
GuruFocus tracks the stock performance after each of Opaleye Management Inc.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Opaleye Management Inc. is 20.15%. GuruFocus also compares Opaleye Management Inc.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Opaleye Management Inc. within 3 months outperforms 55 times out of 87 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Opaleye Management Inc.'s insider trading performs compared to the benchmark.
Performance of Opaleye Management Inc.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 9.95 | | | | | |
| Relative Return to S&P 500(%) | 9.76 | | | | | |
Opaleye Management Inc. Ownership Network
Opaleye Management Inc. Owned Company Details
What does Eton Pharmaceuticals Inc do?
Who are the key executives at Eton Pharmaceuticals Inc?
Opaleye Management Inc. is the 10 percent owner of Eton Pharmaceuticals Inc. Other key executives at Eton Pharmaceuticals Inc include Chief Business Officer David Krempa , director & President & CEO Sean Brynjelsen , and Chief Financial Officer James R. Gruber .
Eton Pharmaceuticals Inc (ETON) Insider Trades Summary
Over the past 18 months, Opaleye Management Inc. made 3 insider transaction in Eton Pharmaceuticals Inc (ETON) with a net purchase of 179,570.
In summary, during the past 3 months, insiders sold 0 shares of Eton Pharmaceuticals Inc (ETON) in total and bought 179,570 shares, with a net purchase of 179,570 shares. During the past 18 months, 0 shares of Eton Pharmaceuticals Inc (ETON) were sold and 179,570 shares were bought by its insiders, resulting in a net purchase of 179,570 shares.
Eton Pharmaceuticals Inc (ETON)'s detailed insider trading history can be found in Insider Trading Tracker table.
Eton Pharmaceuticals Inc Insider Transactions
Opaleye Management Inc. Mailing Address
Above is the net worth, insider trading, and ownership report for Opaleye Management Inc.. You might contact Opaleye Management Inc. via mailing address: One Boston Place, Suite 2600, Boston Ma 02108.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
